Treatment options for patients with metastatic castration-resistant prostate cancer include the use of radioligand therapy with 177Lu-PSMA-617. Although 177Lu-PSMA-617 can selectively target prostate cancer cells, salivary glands express PSMA on the apical lumen of the acinar epithelium. Xerostomia resulting from the use of radioligand therapy is common. Herein, we report on a case of a Common Terminology Criteria for Adverse Events version 5 grade 2 dry mouth event after administration of 177Lu-PSMA-617. The patient was managed with oral hygiene and xerostomia mitigation strategies using oral rinses.
Practical radiation oncology. 2024 Nov 09 [Epub]
Abigail Pepin, Ana Kiess, J Nicholas Lukens, Philipose Mulugeta, Neil K Taunk
Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University, Baltimore, Maryland., Division of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania., Department of Radiation Oncology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: .